Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

← catalyst calendar

NCT06546995

Sponsored by Neumora Therapeutics, Inc. (industry) · NMRA — their whole pipeline →.

Phase

Phase 1

Status

Completed

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

87actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-07-09

actual

When the study began enrolling

Primary completion

2025-11-19

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2025-11-19

actual

The whole study's end, after follow-up

First posted

2024-08-09

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Alzheimer's Disease
Healthy Elderly

Interventions

Drug: NMRA-323511
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Part A: Safety and Tolerability Assessments Based on Treatment Emergent Adverse Events (TEAEs) and Validated Clinical Scales

measured Up to 53 days

Part B: Safety and Tolerability Assessments Based on Treatment Emergent Adverse Events and Validated Clinical Scales

measured Up to Week 10

Part B: Change from Baseline to Week 8 on the Cohen-Mansfield Agitation Inventory (CMAI) Total Score

measured Baseline to Week 8

Permalink · NMRA's whole pipeline · Catalyst calendar · Every registered study · What changed